SK Bioscience Co Ltd
KRX:302440

Watchlist Manager
SK Bioscience Co Ltd Logo
SK Bioscience Co Ltd
KRX:302440
Watchlist
Price: 48 800 KRW -0.31% Market Closed
Market Cap: 3.8T KRW

SK Bioscience Co Ltd
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

SK Bioscience Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
SK Bioscience Co Ltd
KRX:302440
Cash & Cash Equivalents
â‚©312.7B
CAGR 3-Years
47%
CAGR 5-Years
85%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash & Cash Equivalents
â‚©810B
CAGR 3-Years
11%
CAGR 5-Years
4%
CAGR 10-Years
19%
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash & Cash Equivalents
â‚©135.1B
CAGR 3-Years
61%
CAGR 5-Years
44%
CAGR 10-Years
22%
Alteogen Inc
KOSDAQ:196170
Cash & Cash Equivalents
â‚©51.7B
CAGR 3-Years
57%
CAGR 5-Years
51%
CAGR 10-Years
26%
A
ABL Bio Inc
KOSDAQ:298380
Cash & Cash Equivalents
â‚©132.8B
CAGR 3-Years
77%
CAGR 5-Years
4%
CAGR 10-Years
N/A
D
DND PharmaTech Inc
KOSDAQ:347850
Cash & Cash Equivalents
â‚©30B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

SK Bioscience Co Ltd
Glance View

Market Cap
3.8T KRW
Industry
Biotechnology

SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.

Intrinsic Value
38 786.23 KRW
Overvaluation 21%
Intrinsic Value
Price

See Also

What is SK Bioscience Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
312.7B KRW

Based on the financial report for Dec 31, 2024, SK Bioscience Co Ltd's Cash & Cash Equivalents amounts to 312.7B KRW.

What is SK Bioscience Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
85%

Over the last year, the Cash & Cash Equivalents growth was 146%. The average annual Cash & Cash Equivalents growth rates for SK Bioscience Co Ltd have been 47% over the past three years , 85% over the past five years .

Back to Top